Category Archives: pharmaceutical industry

A review of two new books that attack the DSM-5, psychiatry’s “bible”

Share I reviewed two books now circulating about the DSM and the current controversy over the DSM-5 for The American Scholar — see review here. The two books are The Book of Woe: The DSM and the Unmaking of Psychiatry by … Continue reading

Posted in antidepressants, antipsychotic drugs, conflicts of interest, drug marketing, FDA, pharmaceutical industry, prescription drug abuse, scientific misconduct | Tagged , , , , , , , , | Leave a comment

Plot twists in Soderbergh’s new movie Side Effects strain belief

Share I went to see Steven Soderbergh’s new film, Side Effects, with anticipation and dread. The movie, after all, carries the same name as my 2008 book, Side Effects and from what I could tell of the trailers, its plot … Continue reading

Posted in antidepressants, drug marketing, FDA, pharmaceutical industry, prescription drug abuse, university industry collaboration | Tagged , , , , , , , , | 2 Comments

One solution to prescription drug overdoses: make Oyxcontin and similar drugs safer

Share In my previous blogs about West Virginia’s shockingly high rate of prescription drug overdoses — the Mountain State has the second highest rate of overdoses in the nation — I focused on “the culture of disability” that created this … Continue reading

Posted in biotech industry, drug marketing, medical devices, opiods, pharmaceutical industry, prescription drug abuse, public health, Uncategorized | Tagged , , , , , , , | 3 Comments

Why West Virginia has second highest rate of prescription drug overdoses in the nation

Share Did you know that West Virginia has the second highest rate of deaths from prescription drug overdoses in the country? I didn’t, until I moved to the Mountain State to live and work and became curious as to what … Continue reading

Posted in antidepressants, antipsychotic drugs, drug marketing, health care costs, patient care, pharmaceutical industry, prescription drug overdoes, public health | Tagged , , , , , , , , | 5 Comments

Martin Keller, principal investigator of Paxil study 329, retires from Brown University

Share I just learned that Dr. Martin Keller, principal investigator of the controversial Paxil study 329, has retired from his position as a professor of psychiatry at Brown University — see here. As Pharmalot notes, Keller quietly retired June 30 in … Continue reading

Posted in antidepressants, clinical trials, conflicts of interest, drug marketing, ghostwriting, pharmaceutical industry, scientific journal retractions, scientific misconduct | Tagged , , , , , | 2 Comments

Calls for action against authors of controversial Paxil study are getting louder

Share In the wake of GlaxoSmithKline’s record-breaking $3 billion settlement with the U.S. Department of Justice, a number of psychiatrists and researchers have redoubled their efforts to get Paxil study 329 retracted. As mentioned here and in other news accounts, the … Continue reading

Posted in antidepressants, clinical trials, conflicts of interest, drug marketing, ghostwriting, National Institutes of Health, pharmaceutical industry, scientific journal retractions, scientific misconduct, university industry collaboration | Tagged , , , , , , , | 2 Comments

Why academic researchers involved in fraudulent Paxil study escape scrutiny

Share The Chronicle of Higher Education this week ponders why various universities have taken no action against the academic researchers who co-authored the notorious Paxil study that formed the crux of GlaxoSmithKline’s recent $3 billion settlement with the Department of … Continue reading

Posted in antidepressants, clinical trials, National Institutes of Health, pharmaceutical industry, scientific journal retractions, scientific misconduct, university industry collaboration | Tagged , , , , , | 3 Comments

New York AG’s office should take a bow for GlaxoSmithKline’s record-breaking fine

Share I was glad to see that the New York Times‘ reporters covering GlaxoSmithKline’s $3 billion settlement tipped their hat to former New York Attorney General Eliot Spitzer. After all, it was his crew and specifically a pioneering attorney by … Continue reading

Posted in antidepressants, antipsychotic drugs, clinical trials, drug marketing, patient care, pharmaceutical industry, scientific journal retractions, scientific misconduct, suicide rates, whistleblowing | Tagged , , , , , , , | 4 Comments

US Senator raises concerns about possible stock manipulation by Vertex executives

Share Senator Charles Grassley is upping the ante on the controversy surrounding the Vertex pharmaceutical executives who cashed in on overstated clinical trial data — see my blog from last week. According to The Boston Globe, which broke the Vertex … Continue reading

Posted in biotech industry, clinical trials, conflicts of interest, pharmaceutical industry, Uncategorized | Tagged , , , , , , | 1 Comment

Vertex pharmaceutical executives cash in on false hopes

Share Senior executives at Vertex Pharmaceuticals made millions of dollars each by selling company stock in the days after the Cambridge-based pharmaceutical reported promising clinical trial data on an experimental drug for cystic fibrosis. And then weeks after they cashed … Continue reading

Posted in biotech industry, clinical trials, conflicts of interest, drug marketing, pharmaceutical industry, Uncategorized | Tagged , , , , , | 4 Comments